There are around 15 million heart failure patients in Europe and it is thought that between 50% and 75% of these will suffer from sleep-disordered breathing. It is one of the most common heart failure co-morbidities, yet also one of the least diagnosed – despite being clearly linked to poor mortality, hospitalisation and quality of life outcomes. Next year SERVE-HF, the world’s largest randomised trial ever conducted to assess the benefits of effectively treating heart failure patients with sleep-disordered breathing will be reporting results – setting the scene for major changes in how cardiologists view and manage this prevalent co-morbidity.
Most read
